Andover Medical, Inc. Completes Bridge Financing and Names Robert A. Baron to Its Board of Directors.

NORTH ANDOVER, Mass. -- Andover Medical, Inc. (AMI) (OTCBB:ADOV.OB) announced the completion of a bridge financing, and the appointment of Robert A. Baron to its Board of Directors. AMI will use these proceeds and Mr. Baron's insight to further the company's business plan of acquiring organizations in the orthopedic Durable Medical Equipment, urodynamic diagnostic and treatment product industries.

On November 2, 2006, AMI filed a Form 8-K Co announcing the completion of a bridge financing for $673,000 Co to be used for working capital, including expenses incurred in connection with proposed acquisitions. AMI currently has letters of intent with four operating businesses to acquire all of their capital stock. AMI completed its bridge financing with a New York-based investment banking firm. A subsequent Series A financing is targeted to raise $5,000,000 with warrant coverage, if fully exercised, of an additional $15,000,000.

Newly named to AMI's board of directors, Mr. Robert A. Baron has served in executive business roles for 45 years, with successful exits to public companies. He is currently on the boards of organizations such as Exegenics, where he led the winning effort to secure an operating business opportunity; Hemobiotech, a biopharmaceutical business developing a blood substitute product; and NanoSensors, a company developing and manufacturing sensors and devices. Baron obtained a degree in business from the Ohio State University.

The securities sold and to be offered have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This release is not being used for the purpose of conditioning the market in the United States for any of the securities offered or sold.

About Andover Medical, Inc.

Andover Medical, Inc. (AMI) is seeking to take advantage of projected growth and evolving economies of scale arising from consolidation in the procedure specific Durable Medical Equipment (DME) and services segments of the orthopedic, podiatric, and urological physician care markets in the United States. The Company intends to establish a nationwide subsidiary network and plans to offer physicians the largest selection of competitively priced brand-name DME, and urodynamic diagnostic and treatment products.

For more information, please call [phone] or visit www.andovermedical.com

Forward-Looking Statements 

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. All forward-looking statements speak only as of the date of this press release. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, achievements or transactions of AMI and its affiliates to be materially different from any future results, performance, achievements or transactions expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events.